Ann Hematol 84 (Suppl 1): 6166 Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
Therapeutic categories where physicians are reluctant to substitute certain anti-epileptics, thyroid drugs, and immunosuppressants with narrow therapeutic indices also see slower branded erosion
If you experience any suspected side effects, report them to the MHRA Yellow Card Scheme
If you fall in either of these categories, then Wegovy could be right for you
After 50, the body naturally loses muscle mass at a rate of 1-2% per year (sarcopenia), and adding semaglutide-driven calorie restriction on top of age-related muscle loss can be devastating
This insight helps your PlexusDx provider optimize your dose timing and escalation strategy based on your biology